Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
The group’s $8bn acquisition of Merus was the standout in the third quarter.
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
Key FDA decisions are expected to face delays.
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
The Titan CD8-guiding technology seems to have spawned a new variant.
